Table 2.
Optimum ratios of carrier: drugs.
| Drugs | Carriers | Optimum Ratios (Carrier: Drugs) | Date | Reference |
|---|---|---|---|---|
| ASODNs | G5 PAMAM | 1:16 | 2009 | [17] |
| anti-GFP siRNA | G5 PAMAM-RGD | 15:1 | 2009 | [23] |
| anti-GFP siRNA | G5 PAMAM-AC(20,40,60) | 10:1 | 2009 | [27] |
| psiRNA-EGFR | G3 PAMAM -Tat-BMPs | 12.5:1 | 2010 | [18] |
| VEGF siRNA Bcl-2 siRNA |
Au-G5 PAMAM-β-CD | 1:5 | 2018 | [28] |
| SiRNA | (G2-G4) PAMAM-Bis-MPA | 2.5:1 | 2018 | [29] |
| TRAIL | G5 PAMAM-PEG-CTX | 3:1 | 2010 | [30] |
| TRAIL | G5 PAMAM-PEG-Angiopep | 3:1 | 2011 | [15] |
| pORF-hTRAIL | G5 PAMAM-PEG | 3:1 | 2016 | [16] |
| as-miR-21 | G5 PAMAM-5-FU | 16:1 | 2012 | [31] |
| miR-21i | G5 PAMAM | 16:1 | 2012 | [32] |
| pORF-IFN-β plasmid | G4 PAMAM-R | 4:1 | 2013 | [33] |
| miR-7 | PAMAM-FA | 16:1 | 2013 | [24] |
| pJDK-apoptin | G4 PAMAM, G4 PAMAM-R, G4 PAMAM-H-R, G4 PAMAM-H-K | 2:1 | 2017 | [34] |
| G4 PAMAM-FHR | 2:1 | 2019 | [26] | |
| G3 PAMAM-KRRR | 4:1 | 2021 | [35] |
Note: The optimum ratios of the complexes are charge ratios (N/P) that were calculated as a ratio of the number of primary amines in the polymer carrier to the number of anionic phosphate groups in the RNA or DNA.